Forwarded from 미래에셋 제약/바이오 김승민
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
#아델 #오스코텍
https://www.prnewswire.com/news-releases/adel-signs-1-04-billion-global-license-agreement-with-sanofi-for-adel-y01--a-novel-investigational-alzheimers-disease-therapy-302642662.html
#아델 #오스코텍
https://www.prnewswire.com/news-releases/adel-signs-1-04-billion-global-license-agreement-with-sanofi-for-adel-y01--a-novel-investigational-alzheimers-disease-therapy-302642662.html
PR Newswire
ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel investigational Alzheimer's Disease Therapy
/PRNewswire/ -- ADEL, Inc., a biopharmaceutical company dedicated to developing therapies for neurodegenerative diseases such as Alzheimer's Disease, today...
❤1👍1